

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



北京市春立正達醫療器械股份有限公司

Beijing Chunlizhengda Medical Instruments Co., Ltd.*

(A joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1858)

SUPPLEMENTAL ANNOUNCEMENT TO THE ANNUAL REPORT FOR THE YEAR ENDED 31 DECEMBER 2020

Reference is made to the prospectus of Beijing Chunlizhengda Medical Instruments Co., Ltd.* (the “**Company**”, together with its subsidiaries, collectively as the “**Group**”) dated 27 February 2015 (the “**Prospectus**”) and the annual report of the Company for the year ended 31 December 2020 (the “**2020 Annual Report**”). Unless otherwise defined, capitalised terms used in this announcement shall have the same meanings as those defined in the Prospectus and the 2020 Annual Report.

The Board would like to provide additional information in relation to the section headed “Use of proceeds from the global offering” in the 2020 Annual Report in respect of the expected timeline of the use of proceeds pursuant to paragraphs 11(8) and 11A of Appendix 16 of the Listing Rules.

EXPECTED TIMELINE ON THE UNUTILISED NET PROCEEDS

As disclosed in the 2020 Annual Report, the net proceeds received by the Company from the global offering was approximately RMB185.86 million after deducting underwriting commissions and all related expenses. The table below sets forth the status of the use of net proceeds from the global offering as at 31 December 2020, and the expected timeline of the use of the unutilised net proceeds:

Use of Proceeds	Proportion	Amount available (RMB million)	Expense as of 31 December 2020 (RMB million)	Unutilised proceeds as of 31 December 2020 (RMB million)	Expected timeline for the application of the unutilised proceeds
First-installment expense for the development of Daxing New Production Base	50%	92.93	22.46	70.47	By 31 December 2022
Research and development activities	20.20%	37.54	0.8	36.74	By the first half of 2023
Expansion of our existing marketing and distribution network, in order to enhance our market penetration with coverage of more distributors and hospitals for increment of market share	20%	37.17	9.93	27.25	By the first half of 2023
Working capital and other general corporate purposes	9.80%	18.21	18.21	0.00	–
Total	100%	185.86	51.40	134.46	N/A

The expected timeline for utilising the unutilised proceeds is based on the best estimation of the directors of the Company barring unforeseen circumstances, and would be subject to change based on the future development of market conditions.

The above supplementary information does not affect other information contained in the 2020 Annual Report. Save as disclosed in this announcement, the contents of the 2020 Annual Report remains unchanged.

By order of the Board
Beijing Chunlizhengda Medical Instruments Co., Ltd.*
Shi Chunbao
Chairman

Beijing, the PRC, 23 August 2021

As at the date of this announcement, the executive directors of the Company are Mr. Shi Chunbao, Ms. Yue Shujun and Mr. Xie Feng Bao; the non-executive director of the Company is Mr. Wang Xin; and the independent non-executive directors of the Company are Mr. Ge Changyin, Mr. Wong Tak Shing and Mr. Weng Jie.

* For identification purpose only